[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Mirum Pharmaceuticals Inc (MIRM)

Mirum Pharmaceuticals Inc (MIRM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Mirum Pharmaceuticals Inc 989 EAST HILLSDALE BOULEVARD SUITE 300 FOSTER CITY CA 94404 USA

www.mirumpharma.com Employees: 372 P: 650-667-4085

Sector:

Medical

Description:

Mirum Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company's product candidate consists of maralixibat, an investigational oral drug in development for progressive familial intrahepatic cholestasis and Alagille syndrome. Mirum Pharmaceuticals Inc. is based in Foster City, United States.

Key Statistics

Overview:

Market Capitalization, $K 5,520,689
Enterprise Value, $K 5,224,009
Shares Outstanding, K 60,342
Float, K 51,677
% Float 85.64%
Short Interest, K 8,214
Short Float 13.61%
Days to Cover 12.54
Short Volume Ratio 0.66
% of Insider Shareholders 14.36%

Financials:

Annual Sales, $ 521,310 K
Annual Net Income, $ -23,360 K
Last Quarter Sales, $ 148,930 K
Last Quarter Net Income, $ -5,730 K
EBIT, $ -22,140 K
EBITDA, $ 3,840 K

Growth:

1-Year Return 126.67%
3-Year Return 240.74%
5-Year Return 368.22%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 88.51%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.11 on 02/25/26
Next Earnings Date 05/06/26 [--]
Earnings Per Share ttm -0.48
EPS Growth vs. Prev Qtr -320.00%
EPS Growth vs. Prev Year 77.55%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

MIRM Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -8.53%
Return-on-Assets % -3.07%
Profit Margin % -4.48%
Debt/Equity 0.00
Price/Sales 10.64
Price/Cash Flow 1,803.68
Price/Book 15.02
Book Value/Share 6.12
Interest Coverage -0.49
60-Month Beta 0.51
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.